Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework
{{output}}
Therapeutic proteins are central to modern pharmacotherapy, yet their clinical utility is often constrained by short plasma half-life and immunogenicity. Six major half-life extension platforms-PEGylation, hydrophilic polypeptide (XTEN/PAS) fusion, glycoengine... ...
